Kymera rais­es $65M from glob­al syn­di­cate as it aims for the clin­ic with pro­tein degra­da­tion tech

7 years ago
Financing

As Roivant’s uni­corn val­u­a­tion swells to $7B, Ra­maswamy scoops up $200M to back a new burst of star­tups

7 years ago
Financing

On the heels of an Eli Lil­ly deal, NextCure’s hot hand in I/O at­tracts a $93M trans-Pa­cif­ic ven­ture round

7 years ago
Financing

Mer­ck, Am­gen back a $30M play for Ri­bometrix — one of the up­starts mak­ing its mark in drug­ging RNA

7 years ago
Financing

Con­cert’s ini­tial alope­cia da­ta fall short against Pfiz­er, prompt­ing in­vestor blow back

7 years ago
R&D

Nestlé ups its bet on Aim­mune’s peanut al­ler­gy drug to $276M as NDA fil­ing looms, ri­val­ry in­ten­si­fies

7 years ago
Pharma

Or­biMed leads $70M raise for Har­poon Ther­a­peu­tics; Zio­pharm inks com­bo deal with Re­gen­eron's PD-1

7 years ago
News Briefing

No­var­tis builds block­buster case for En­tresto, beat­ing out a cheap ACE in­hibitor — or not

7 years ago
R&D

With the $62B Shire buy­out on track, Take­da plans to de­but the new­ly merged com­pa­ny at JP­Mor­gan

7 years ago
Deals

Boehringer backs $33M can­cer vac­cine play at Switzer­land's AMAL Ther­a­peu­tics

7 years ago
Financing

Amarin just rolled out a bat­tery of promis­ing new da­ta for Vas­cepa — brace your­self for the M&A chat­ter to come

7 years ago
R&D

#SITC18: An­oth­er un­der­whelm­ing per­for­mance for STING dam­ages Aduro’s al­ready suf­fer­ing share price

7 years ago
R&D

The lat­est up­date on NK­TR-214/Op­di­vo from Nek­tar and Bris­tol-My­ers will keep the con­tro­ver­sy burn­ing over the ORR ...

7 years ago
R&D

Big dreams, big pay and a big IPO: Mod­er­na lights up a pitch for a record $500M biotech IPO

7 years ago
Financing

FDA looks to strength­en ex­pand­ed ac­cess pro­gram

7 years ago
Pharma

One year in, Joanne Kotz as­sumes CEO role at Jnana; Pres­i­dent/Ex­ec­u­tive chair duo will now run Black­Thorn

7 years ago
Peer Review

Genen­tech de­tails claims Sanofi part­ner JHL used stolen trade se­crets to de­vel­op ri­val drugs at an 'as­ton­ish­ing pace'

7 years ago
R&D
Pharma

In­novent, Eli Lil­ly cite a new suc­cess for their PD-1 in lung can­cer, with a like­ly pi­o­neer­ing ap­proval in Chi­na ...

7 years ago
R&D
China

Sarep­ta shares sink on the back of a mon­ster $500M raise

7 years ago
Cell/Gene Tx

Bil­lion­aire gifts Har­vard a his­toric $200M to 'ex­pe­dite' trans­la­tion­al bio­med­ical re­search work

7 years ago
People
Discovery

Penn spin­out preps for hu­man stud­ies of a new-mod­el CAAR, aim­ing at a one-time cure for au­toim­mune dis­eases

7 years ago
Financing
Startups

Ab­b­Vie hatch­es plans for a ma­jor new R&D hub close to its part­ners in Bay Area's buzzy Oys­ter Point

7 years ago
R&D
Pharma

Bio­Marin looks for fast ap­proval of he­mo­phil­ia A gene ther­a­py; In­ves­ti­ga­tors tout En­ta­sis an­tibi­ot­ic

7 years ago
News Briefing

Drug­mak­ers seek clar­i­ty on guid­ance on use of place­bo and blind­ing in on­col­o­gy tri­als

7 years ago
Pharma
First page Previous page 996997998999100010011002 Next page Last page
A service from the Financial Times